On the afternoon of November 9, the “Rui List of China Pharmaceutical Brand 2017” was launched during a session of National Medical Conference on Economic Information, where a grand award presentation ceremony was held. 36 brands in 17 categories, including Jiangsu Hansoh Pharmaceutical Group’s new oncology drug Xinwei imatinib mesylate tablets were successfully listed.
Xinwei imatinib mesylate tablets, the drug which made to the list and made by Hansoh Pharmaceutical Group, is used to treat leukemia. According to the data released by the financial, transportation, public and other television channels and media outlets of Jiangsu Radio and Television Group, the drug successfully transformed leukemia from a low survival deadly disease into a chronic disease that allows for long-term medication, and it broke the market monopoly of multi-national companies with its unique technological innovation and key breakthroughs (technology patents recognized by the State Intellectual Property Office) by reducing the cost of treatment to 1/8 to 1/10 of that of the originator drug. After the drug was launched in 2014, its efficacy was widely recognized and accepted by doctors and patients. On the basis of quality excellence, because of its huge competitive advantage, it has quickly gained market shares after launch, and experienced strong groth in the past three years. Moreover, in response to the increasing demand of patients, the drug was included in the national medical insurance program in August this year. Its rapid market expansion is expected to continue in the future.
The company has gained word-of-mouth reputation by remaining true to its original aspiration and its craftsmanship. Technological innovation and lean and smart manufacturing lies at the heart of Hansoh’s high market acceptance and competitiveness. In the future, Hansoh Pharma will continue to uphold its corporate mission of “serve the society and build a healthy world”, helping patients to return to healthy life with high-quality products. In the meanwhile, we will actively invest in academic transformation and talent development in the pharmaceutical industry, and work more scientifically and intensely to respond to the national strategies, helping to eliminate the contradiction between unbalanced and inadequate development and the people's ever-growing needs for a better life.
The “Rui List of China Pharmaceutical Brand 2017”used the high growth new brands appeared in the “hospital terminal”, “grass root terminal” and “retail terminal” in the past year of monitoring terminals of menet.com as reference coefficients (2016).
Source text link: https://mp.weixin.qq.com/s/ZZQfsZTtMQ2tZTXIgT7zaA#rd
